Cytodyn Inc (CYDY)

[DonDonDonDon]

CytoDyn's leronlimab offers the best "shot" going, for recovery. In fact - why wait until you're almost dead to begin treatment?

CytoDyn has released zero topline data from the severe patients of the S/C trial despite severe patients making up 5/6ths of the trial. Obviously, leronlimab completely failed with severe patients. But you're right, there is no reason why it would work with critical patients and not severe patients. The fact that it failed the 331 severe patients takes away the credibility of positive data from the 62 critical patients.